프리마켓
로그인 회원가입
PASG
PASG
Passage Bio Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$4.62
-0.32 ▼ -6.48%
🌙 7월 28일 4:07 AM ET (한국 7/28 17:07)
$4.76
+0.14 ▲ +3.03%

패시지 바이오(PASG) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$15M
스몰캡
P/E
-
배당수익률
없음
52주 위치
8%
저점 +40% · 고점 -77%
애널리스트
매수
C+
Fundamental health
vs. 성장주 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 51%
밸류에이션
데이터 부족
재무 안정
Top 48%
Index -P/E -EPS (ttm) -11.84Insider Own 7.72%Shs Outstand 3.2MPerf Week -3.95%
Market Cap 0.01BForward P/E -EPS next Y 7.08%Insider Trans 25.29%Shs Float 3.0MPerf Month 6.7%
Enterprise Value -0.01BPEG -EPS next Q -2.65Inst Own 57.43%Short Float 4.21%Perf Quarter -20.89%
Income -0.04BP/S -EPS this Y 27.27%Inst Trans 17.95%Short Ratio 1.42Perf Half Y -63.28%
Sales 0.00BP/B 1.26EPS next 5Y 14.82%ROA -61.53%Short Interest 0.12MPerf YTD -60.85%
Book/sh 3.66P/C 0.45EPS past 3/5Y 34.05% 24.41%ROE -128.9%52W High -76.9% ($20.00)Perf Year -37.9%
Cash/sh 10.38P/FCF -Sales past 3/5Y -ROIC -230.32%52W Low 40.43% ($3.29)Perf 3Y -72.76%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 42.29%Gross Margin -Volatility(W/M) 4.98% 9.58%Perf 5Y -98.16%
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 0.39Perf 10Y -
Dividend Ex-Date -Quick Ratio 1.73EPS Q/Q 52.47%Profit Margin -RSI (14) 42.26Recom 2.33
Dividend Gr. 3/5Y -Current Ratio 1.73Sales Q/Q -SMA20 -3.19% ($4.77)Beta 1.42Target Price $15.5
Payout -Debt/Eq 0.49Earnings 2026/05/19SMA50 -11.13% ($5.2)Rel Volume 0.34Prev Close $4.94
Employees 24LT Debt/Eq 0.39EPS/Sales Surpr. 5.69% -SMA200 -42.87% ($8.09)Avg Volume(3M) 0.09MPrice $4.62
IPO 2020/2/28Option/Short No/YesTrades 247Volume 29,520Change -6.48%
Quarterly earnings trend SEC filings · USD
23.9
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-8M (YoY +51%)

📊 Passage Bio Inc (PASG) Investment Analysis

What kind of company is Passage Bio Inc?

패시지 바이오(PASG) 성장주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

Passage Bio is a clinical-stage biotech developing AAV-based gene therapies targeting rare central nervous system (CNS) diseases. The company has built its pipeline through a strategic collaboration with the University of Pennsylvania's Gene Therapy Program, with a primary focus on pediatric and adult rare CNS conditions that have very few treatment alternatives, including frontotemporal dementia with progranulin mutations (FTD-GRN), Krabbe disease, and GM1 gangliosidosis.

Learn more about Passage Bio Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5360
Employees24people
IPO2020/02/28
Current Price$4.62 ≈ 6,329원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 19일 (화) · 장 마감 후 EPS +5.7%
🔔 Earnings release 2026년 3월 3일 (화) · 장 시작 전 EPS -59.3%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-128.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-61.5%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-230.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.49
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
1.73
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.73
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$15.50
현재가 대비 +235.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+7.1%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+14.8%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
-20.3%
평균 서프라이즈
2026.05.19
상회
+5.7%
2026.03.03
하회
실적 $-4.09 · 예상 $-2.80 -46.3%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+27.3%
양호
My positionMid-range
Low range Average High range
성장주 초소형주 Median 21.2% · Top 44%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+7.1%
평균
My positionMid-range
Low range Average High range
성장주 초소형주 Median 13.9% · Bottom 34%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+14.8%
부진
My positionBottom 25%
Low range Average High range
성장주 초소형주 Median 21.6% · Bottom 19%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+34.0%
양호
My positionMid-range
Low range Average High range
성장주 초소형주 Median 24.8% · Top 36%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+24.4%
양호
My positionMid-range
Low range Average High range
성장주 초소형주 Median 12.0% · Top 30%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -167%p below the market
PASG -98.2% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-166.5%p
Significantly behind the market
vs Health Care (XLV)
-122.7%p
Significantly behind the sector average
1-year basis
vs S&P 500
-53.9%p
Significantly behind the market
vs Health Care (XLV)
-57.6%p
Significantly behind the sector average
Rank among peers
5-year return Lower-Mid (lower 36%) Based on 245 peers
1-year return Upper-Mid (44%) Based on 315 peers
Current position within 52-week range
Low (-40.4%p) High (-76.9%p)
Current price is 40.4% above the 52-week low and 76.9% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-65.7%
Annualized volatility
134.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $4.62 below the midline ($4.77). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD -0.121 · Signal -0.159 · Hist 0.038. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 42.3 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 48.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.26x
✓ Cheap
My positionMid-range
Low range Average High range
Biotechnology 초소형주 median 1.35x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$15.50 vs. current price +235.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Insider net buying +25.3% · Institutional net buying +17.9% · Short interest light 4.2% · Short interest up +1.3pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
+25.3%
Insiders large net buying
🏦 Institutions (funds & investors)
+17.9%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 57.4%
Adequate institutional weight
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 7.7%
Meaningful insider stake
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 34.8%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
4.2%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 90 days 📈 +1.3%p increase
Short interest days to cover
1.4 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 3.2M주
Float (tradable shares) 3.0M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding PASG

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
PASG PASG This Stock
$14.8M- 1.3 -128.9% - -6.5%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 패시지 바이오(PASG)?

패시지 바이오(PASG) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of PASG?

The market cap of PASG is approximately $15M, ranking 5,360 within its sector.

What is the 52-week high and low for PASG?

PASG has recorded a 52-week high of $20.00 and a low of $3.29.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.